Adagene and Third Arc Bio Select First Lead Candidate
San Diego, California, and Suzhou, China, September 10, 2026 Adagene Inc. and Third Arc Bio, Inc. have announced the...
ADC AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
San Diego, California, and Suzhou, China, September 10, 2026 Adagene Inc. and Third Arc Bio, Inc. have announced the...
Burlington, Massachusetts, U.S., September 10, 2026 Consano Bio, Inc. has announced the publication of peer-reviewed nonclinical research evaluating C-1101,...
